- Home
- SANA vs TSHA Comparison
SANA vs TSHA Comparison
Compare SANA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SANA | TSHA |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SANA | TSHA |
|---|---|---|
| Price | $4.75 | $4.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $7.83 | ★ $10.56 |
| AVG Volume (30 Days) | 2.6M | ★ 2.7M |
| Earning Date | 03-16-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $1.05 |
| 52 Week High | $6.55 | $6.02 |
Technical Indicators
Market Signals| Indicator | SANA | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 40.79 |
| Support Level | $4.61 | $4.50 |
| Resistance Level | $5.20 | $4.89 |
| Average True Range (ATR) | 0.32 | 0.31 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 51.00 | 12.06 |
Price Performance
Historical ComparisonAbout SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.